Researchers in the US and Europe are implementing pathogen sequencing surveillance programs to track infectious diseases within hospitals.
The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.
The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
Researchers examine what motivates people to become donors for fecal microbiome transplants, according to the New York Times.
"Repurposing starts with the human genome," a precision medicine expert said in explaining Vanderbilt's new approach to accelerating clinical trials.
An analysis of metagenomic sequences from donor and recipient stool samples highlighted bacterial abundance, phylogeny, and strain features influencing engraftment.
Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
The Québec-based firm launched the test, which detects the toxin B gene of toxigenic C. diff strains directly from stool samples, in the US today.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.